Third Harmonic Bio Past Earnings Performance
Past criteria checks 0/6
Third Harmonic Bio's earnings have been declining at an average annual rate of -9.9%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-9.9%
Earnings growth rate
60.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -13.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Third Harmonic Bio (NASDAQ:THRD) Is In A Good Position To Deliver On Growth Plans
Nov 16
Companies Like Third Harmonic Bio (NASDAQ:THRD) Can Afford To Invest In Growth
Aug 03Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation
Apr 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
Sep 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
May 02We're Not Very Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Rate
Dec 16Revenue & Expenses Breakdown
How Third Harmonic Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -39 | 21 | 32 |
| 30 Jun 24 | 0 | -33 | 20 | 27 |
| 31 Mar 24 | 0 | -30 | 20 | 23 |
| 31 Dec 23 | 0 | -31 | 20 | 24 |
| 30 Sep 23 | 0 | -35 | 20 | 27 |
| 30 Jun 23 | 0 | -36 | 19 | 26 |
| 31 Mar 23 | 0 | -36 | 17 | 25 |
| 31 Dec 22 | 0 | -35 | 13 | 24 |
| 30 Sep 22 | 0 | -39 | 10 | 19 |
| 30 Jun 22 | 0 | -39 | 7 | 20 |
| 31 Mar 22 | 0 | -34 | 4 | 19 |
| 31 Dec 21 | 0 | -30 | 3 | 16 |
Quality Earnings: THRD is currently unprofitable.
Growing Profit Margin: THRD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: THRD is unprofitable, and losses have increased over the past 5 years at a rate of 9.9% per year.
Accelerating Growth: Unable to compare THRD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: THRD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: THRD has a negative Return on Equity (-13.29%), as it is currently unprofitable.